SenzaGen AB (SENZA.ST) Stock Analysis & Winston Score

SenzaGen is a Swedish biotech company that helps chemical and cosmetics manufacturers test whether their products might cause skin allergies. Instead of using animal testing, SenzaGen sells lab-based tests that mimic how human skin reacts to chemicals. Its main customers are companies in industries like cosmetics, pharmaceuticals, and industrial chemicals that need to prove their products are safe before selling them. The company earns money by selling its testing kits and services to labs and manufacturers around the world, primarily in Europe and North America. Its core product, GARD, is a patented human cell-based test, which gives SenzaGen a degree of scientific differentiation in a market shifting away from animal testing due to tightening regulations in the EU and elsewhere. The main growth driver is the global push to ban animal testing in safety assessments, but the key risk is that SenzaGen is still small, unprofitable, and competing against larger, well-funded diagnostics companies for adoption of its technology.